Immunity to visceral leishmaniasis: implications for immunotherapy

Area of Science:

• Parasitology
• Immunology
• Tropical Medicine

Background:

• Visceral leishmaniasis (VL) is a significant global health concern caused by Leishmania parasites, with 400,000 new infections annually.
• VL is the most severe form of leishmaniasis, characterized by high mortality and morbidity, and is expanding into new regions.
• Challenges include emerging Leishmania-HIV co-infection and increasing drug-resistant strains, alongside toxic side effects of current treatments.

Purpose of the Study:

• To provide a comprehensive overview of visceral leishmaniasis.
• To emphasize the critical role of innate and adaptive immune responses in disease pathogenesis and protection.
• To explore current and potential vaccine and immunotherapy strategies for VL.

Main Methods:

• Literature review focusing on immunology, epidemiology, and therapeutic strategies for visceral leishmaniasis.
• Analysis of innate and adaptive immune mechanisms relevant to Leishmania donovani and Leishmania infantum infections.
• Evaluation of vaccine and immunotherapy approaches, including their potential and limitations.

Main Results:

• The review details the complex interplay of immune cells and cytokines in controlling or exacerbating VL.
• It highlights the limitations of existing drugs and the urgent need for novel interventions.
• Various vaccine candidates and immunotherapeutic strategies are discussed, with varying degrees of preclinical and clinical success.

Conclusions:

• A thorough understanding of protective immunity against visceral leishmaniasis is essential for developing new vaccines and immunotherapies.
• Addressing drug resistance and co-infections requires innovative therapeutic and prophylactic approaches.
• Further research into host-parasite interactions and immune modulation holds promise for controlling VL.